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Objective: To evaluate the effects of platelet-rich plasma (PRP) inﬁltration in patients with
lateral epicondylitis of the elbow, through analysis of the Disabilities of the Arm, Shoulder
and Hand (DASH) and Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaires.
Methods: Sixty patients with lateral epicondylitis of the elbow were prospectively random-
ized  and evaluated after receiving inﬁltration of three milliliters of PRP, or 0.5% neocaine,
or  dexamethasone. For the scoring process, the patients were asked to ﬁll out the DASH
and PRTEE questionnaires on three occasions: on the day of inﬁltration and 90 and 180 days
afterwards.
Results: Around 81.7% of the patients who underwent the treatment presented some
improvement of the symptoms. The statistical tests showed that there was evidence that
the  cure rate was unrelated to the substance applied (p = 0.62). There was also intersection
between the conﬁdence intervals of each group, thus demonstrating that the proportions of
patients whose symptoms improved were similar in all the groups.
Conclusion: At a signiﬁcance level of 5%, there was no evidence that one treatment was more
effective than another, when assessed using the DASH and PRTEE questionnaires.© 2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved. Work developed in the Department of Orthopedics, Traumatology and Sports and Exercise Medicine, Faculdade de Medicina de Marília
(FAMEMA), Marília, SP, Brazil.
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http://dx.doi.org/10.1016/j.rboe.2015.03.014
2255-4971/© 2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora Ltda. All rights reserved.
r e v b r a s o r t o p . 2 0 1 6;5 1(1):90–95 91
Efeitos  do  plasma  rico  em  plaquetas  na  epicondilite  lateral  do  cotovelo:
estudo  prospectivo,  randomizado  e  controlado
Palavras-chave:
Plasma rico em plaquetas
Tendinopatia
Cotovelo do tenista
r  e  s  u  m  o
Objetivo: Avaliar os efeitos da inﬁltrac¸ão do plasma rico em plaquetas (PRP) em pacientes
com  epicondilite lateral do cotovelo (ELC) pela análise dos questionários Deﬁciência do
Brac¸o,  Ombro e Mão (Dash) e Avaliac¸ão do Paciente Portador do Cotovelo de Tenista (PRTEE).
Métodos: Foram randomizados e avaliados prospectivamente 60 pacientes, após receberem
inﬁltrac¸ões  de três mililitros de PRP, ou neocaína 0,5%, ou dexametasona. Para o processo
de  pontuac¸ão, os pacientes foram convidados a preencher os questionários Dash e PRTEE
em  três ocasiões: no dia da inﬁltrac¸ão, 90 e 180 dias após.
Resultados: Dos pacientes submetidos ao tratamento, 81,7% apresentaram melhoria dos
sintomas. Os testes estatísticos demonstraram que há evidências de que a taxa de cura
não  está relacionada com a substância aplicada (p = 0,62). Houve também intersec¸ão dos
intervalos de conﬁanc¸a de cada grupo, com demonstrac¸ão de que as proporc¸ões de pacientes
cujos sintomas melhoraram foram semelhantes em todos os grupos.
Conclusão: Em um nível de signiﬁcância de 5%, não houve evidência de que um tratamento
foi  mais eﬁcaz do que a outro, quando avaliados pelos questionários Dash e PRTEE.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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of 18 years and positive ﬁndings from two of the followingntroduction
ateral epicondylitis of the elbow is a disease that mainly
ffects individuals who  make repetitive movements with their
rists and/or ﬁngers.1 The name “tennis elbow” does not
orrespond to the reality. Although around 40–50% of tennis
layers present this disease, especially those who have been
racticing this sport for longer times,2 this group accounts
or only 5% of the total number of individuals affected.3,4
lthough the term “lateral epicondylitis of the elbow” may
lso be inappropriate, given that this pathological condition
oes not involve a truly inﬂammatory process, but rather, a
egenerative process,5–8 it will be used in this study because
t has been widely disseminated in the literature.
This injury predominantly involves the origin of the short
adial extensor muscle of the carpus, in which microtears
evelop as a result of excessive and abnormal use, with for-
ation of immature repair tissue.5
The symptoms of lateral epicondylitis of the elbow are gen-
rally self-limited and may vary in duration from a few weeks
o months. However, in some cases, there is no spontaneous
esolution of the symptoms, and this invariably leads to a
hronic condition.9,10 It also has to be borne in mind that lat-
ral epicondylitis of the elbow is associated with long periods
ff work, which gives rise to high social security costs and
ubstantial loss of professional productivity.11–14
There is relatively little evidence based on good-quality
linical studies to support the various forms of treatment for
ateral epicondylitis of the elbow that have been described
n the literature. The treatment options range from rela-
ive rest in association with immobilization, physiotherapy,
pplication of botulinum toxin, acupuncture, shockwave
herapy, use of oral non-steroidal anti-inﬂammatory drugs,
teroid injections and, most recently, use of platelet-richplasma.15–20 Surgical procedures are only recommended when
the symptoms last for more  than six months and/or if other
non-surgical treatment options have failed.5,17,20
Given the high incidence of this disease, the expenditure
that results from its treatment and, especially, the lack of con-
sensus in the different databases available and in particular
the Brazilian orthopedic databases, we proposed the present
study. Its aim was to prospectively compare the results from
three different options for treating lateral epicondylitis of the
elbow, using the DASH and PRTEE questionnaires, which have
recently been translated and validated for use in Portuguese.
Material  and  methods
Participants  and  study  design
The protocol for this study was approved by the Ethics Com-
mittee for Research Involving Human Beings, under no. 453/12.
All the patients or their guardians agreed to participate in
the study through signing a free and informed consent state-
ment, after having been given detailed information about the
content and form of the study.
The sample size was determined before starting the study.
The  ˛ and  ˇ risks (respectively 5% and 20%) and the variability
of the variables (p1 = 0.2 and p2 = 0.63) were taken into account,
and a minimum number of 20 participants per group was thus
determined.
Between February 2012 and February 2014, 72 consecutive
patients with lateral epicondylitis of the elbow were selected
for the study. The inclusion criteria were a minimum ageclinical tests: Cozen, Mill, Gardner and Maudsley. The fol-
lowing patients were excluded: those who  had undergone
some form of previous treatment in the elbow region; those
 p . 2 0 1 6;5  1(1):90–95
Fig. 1 – Preparation of the platelet-rich plasma.
Fig. 2 – Identiﬁcation of the inﬁltration site (circled) and the92  r e v b r a s o r t o
who  presented other diseases in the upper limbs (such as
posterior interosseous nerve syndrome and/or carpal tunnel
syndrome): patients with systemic diseases (such as dia-
betes mellitus, hypothyroidism and/or rheumatoid arthritis);
pregnant patients; and lastly, patients using contraceptive
drugs.10,11 Ultrasound examinations were performed only to
document the cases and form an image  database. Through
applying the criteria, 60 patients were included in this
study.
Instruments
The instruments most used for measuring the functionality
and degree of impairment of patients’ elbow region are the
Disabilities of the Arm, Shoulder and Hand (DASH) question-
naire and the Patient-Rated Tennis Elbow Evaluation (PRTEE).
Both of these instruments have been validated for use in
Portuguese. The DASH questionnaire measures the incapac-
ity of the upper limb as a single unit, always from the
patient’s perspective.12,14,15 On the other hand, the PRTEE
was developed solely to evaluate lateral epicondylitis of the
elbow.
Both questionnaires were applied to all the patients at
three different times: on the day of inﬁltration (DASH-0 and
PRTEE-0), 90 days afterwards (DASH-90 and PRTEE-90) and 180
days afterwards (DASH-180 and PRTEE-180).
Blinding  and  randomization  process
With the aim of ensuring greater reliability for the results and
greater investigative power for the study, it was decided to
institute a process of triple blinding.
The randomization process consisted of the method of
sealed opaque envelopes.21,22 The allocation group was stated
inside each envelope: group A (n = 20; 5% neocaine), group B
(n = 20; dexamethasone) and group C (n = 20; PRP).
Preparation  and  application  of  platelet-rich  plasma
The PRP used in this study was obtained as recommended by
Vendramin et al.23 60 ml  of blood that had previously been
taken from each patient was divided between six 10 ml  tubes
that contained sodium citrate. These tubes were then sub-
jected to two cycles of centrifugation, under forces of 400 g
and 800 g, for 10 min.
Two thirds of the original volume (platelet-poor plasma)
was discarded in this method. Only one third of the original
blood sample consisted of PRP (Fig. 1).
Finger pressure was applied locally to the patients so that
they could identify the region of greatest pain (Fig. 2). Before
placement of sterile ocular ﬁelds, asepsis and antisepsis pro-
cedures were performed using chlorhexidine. The patients in
group A then underwent local inﬁltration of 3 ml  of 0.5% neo-
caine; group B received inﬁltration of 3 ml  of dexamethasone
acetate; and group C received inﬁltration of 3 ml  of platelet-
rich plasma. All the syringes were covered with a double layer
of aluminum foil, for the inﬁltration procedure, by a person
who  was unconnected to the study.posterior interosseous nerve (PIN).
Statistical  analysis
To perform the statistical calculations, the software used
comprised SigmaStat® 3.5 (Systat Software Inc., 2006) and
Minitab® version 15 (Minitab Inc., 2007), The signiﬁcance level
was taken to be 5% (p < 0.05).
The variables were analyzed by means of descriptive,
parametric and nonparametric statistical tests in a fully
randomized model. The parametric option was used when
the variable presented Gaussian behavior (Student’s t test
and ANOVA). If the distribution was non-Gaussian, the non-
parametric option was indicated (Mann–Whitney U test and
Fisher’s exact test). The mean values, standard deviations,
medians, frequencies, percentages and 95% conﬁdence inter-
vals (CI) were calculated (  ˛ = 5%).
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Table 3 – Scores from the PRTEE-0 questionnaires in the
three groups.
Group Minimum
score
Maximum
score
Median Mean Standard
error
A 18.0 82.5 52.5 51.7 4.4
B 17.0 83.5 35.8 42.9 4.3
C 24.5 88.5 37.0 47.1 4.9
Table 4 – Scores from the PRTEE-90 questionnaires in the
three groups.
Group Minimum
score
Maximum
score
Median  Mean Standard
error
A 1.5 80.0 9.5 15.5 3.9
B 0.0 85.0 12.8 21.8 5.5
C 0.5 91.5 6.5 13.0 4.7
Table 5 – Difference between the DASH-0 and DASH-90
questionnaires (scores ≥ 15).
Group n % Standard error 95% CI
A 20 90.0 6.8 [68.3–98.8] = 0.99).
esults
he ages in group A ranged from 22 to 85 years (mean: 47.9;
5% CI: 42.2–53.6 years); in group B the range was from 19 to
1 years (mean: 46.2; 95% CI: 41–51.5 years); and in group C it
as from 26 to 61 years (mean: 46.6; 95% CI: 41.6–51.6 years)
Kruskal–Wallis; p = 0.99) (Fig. 3).
In all three groups, the score in the DASH-90 questionnaire
as lower than the score in DASH-0, although the maximum
alues found in DASH-90 were greater than those in DASH-0.
his discrepancy can be explained by the scores attributed to
 single patient, which reached 75.8 and 80.8 points in the
ASH-0 and DASH-90 questionnaires, respectively. Further-
ore,  another participant had a lower score in DASH-0 (34.2)han in DASH-90 (37.5). For the same reasons, slightly higher
tandard error values can be seen in DASH-90 than in DASH-0
Table 1 – Scores from the DASH-0 questionnaires in the
three groups.
Group Minimum
score
Maximum
score
Median Mean Standard
error
A 25.0 73.3 49.2 49.7 3.0
B 15.0 75.8 40.4 44.3 4.4
C 22.5 82.5 40.8 45.7 3.8
Table 2 – Scores from the DASH-90 questionnaires in the
three groups.
Group Minimum
score
Maximum
score
Median Mean Standard
error
A 0.8 71.7 10.2 16.6 3.8
B 0.0 80.8 12.1 19.8 4.9
C 1.7 79.2 5.0 10.7 4.0B 20 65.0 10.9 [40.8–94.6]
C 20 90.0 6.8 [68.3–98.8]
(Tables 1 and 2). The values from the DASH-180 questionnaires
were taken to be zero in all three groups.
In relation to the PRTEE questionnaire, it was noted that in
all three groups, the scores relating to PRTEE-90 were lower
than those of PRTEE-0. However, the maximum scores in
groups B and C were higher in PRTEE-90 than in PRTEE-0. This
discrepancy can be explained by the scores of a single par-
ticipant who reached 65.5 points (PRTEE-0) and 85.0 points
(PRTEE-90), both in group B; and another patient who  reached
scores of 83.0 (PRTEE-0) and 91.5 (PRTEE-90), both in group C.
It is also important to note that another ﬁve individuals pre-
sented higher scores in PRTEE-90 (two in group A, two  in group
B and one in group C) (Tables 3 and 4). The values from the
PRTEE-180 questionnaires were taken to be zero in all three
groups.
Table 5 shows the absolute quantity (n) and proportion (%)
of the patients who reported achieving some improvement in
symptoms, as demonstrated by a difference greater than or
equal to 15 points (binomial distribution) between the DASH-
0 and DASH-90 questionnaires. The values from the PRTEE-180
questionnaires were taken to be zero in all three groups.
Overall, 81.7% of the patients had some improvement in
their symptoms. In groups A and C, there were reports of
improvement in 90% of the cases and in group B the propor-
tion was 65% (p = 0.62). IN other words, there was evidence that
the proportion of care was unrelated to the substance used, at
the signiﬁcance level of 5%. Moreover, the conﬁdence intervals
correlated between the groups, which shows that the propor-
tion of improvement of symptoms was the same in the three
groups.
In order to conﬁrm the results from the DASH question-
naires, the proportions of improvement were matches and
compared using Student’s t test. For the pairings A/B and B/C,
the proportions were statistically the same (p = 0.56), and also
in the pairing A/C (p = 0.41).
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Table 6 – Difference between the PRTEE-0 and PRTEE-90
questionnaires (scores ≥ 7).
Group n % Standard error 95% CI
A 20 90.0 6.8 [68.3–98.8]
B 20 85.0 8.2 [62.1–96.8]
C 20 90.0 6.9  [68.3–98.8]
Table 7 – Kappa test for intraobserver analysis on
improvement of symptoms (DASH and PRTEE).
PRTEE
Without
improvement
With
improvement
Total
Dash
Without improvement 10.0 8.3 18.3
With improvement 1.7 80.0 81.7
r
strategies. Am J Sports Med. 1979;7(4):234–8.
3. Assendelft WJJ,  Hay EM, Adshead R, Bouter LM. CorticosteroidTotal 11.7 88.3 100
Improvement of the symptoms in the PRTEE questionnaire
was deﬁned as a difference in scores between the question-
naires greater than or equal to 7 points. In this study, 90% of
the participants in groups A and C reported achieving improve-
ments, as did 85% in group B. The test of independence
between the groups did not present statistical signiﬁcance
(p = 0.85) (Table 6). In the same way as in the DASH question-
naire, there was evidence that the proportion that achieved a
cure did not depend on the substance used, at the signiﬁcance
level of 5%.
Once again, in order to conﬁrm the results from the
PRTEE questionnaires, the proportions of improvement were
matched and compared using Student’s t test. In relation to the
pairings A/B, B/C and A/C, the proportions were statistically
the same (p = 0.66).
Table 7 shows the results from the kappa test, for inter-
observer agreement relating to the questionnaires that were
applied. It could be seen that there was substantial agree-
ment between the two questionnaires (p = 0.6). In relation to
the internal concordance of the questionnaires, Cronbach’s
alpha test showed that there was consistency between the
questionnaires (p = 0.8).
Discussion
Visual analogue scales (VAS) for assessing pain are the most
commonly used method for measuring painful conditions
because they are quickly and easily applied. However, using
VAS presents practical limitations within clinical scenarios,
given that most patients report that they have difﬁculty in
translating the physical intensity of their pain into a scale in
millimeters.20
Several mechanisms of action for PRP have been described
in the literature. In principle, these explain the clinical
improvement of the participants in this study: the local hemo-
static action of the substance during the postoperative period,
along with its inﬂuence on osteogenesis and soft-tissue heal-
ing, especially muscle healing.11 There is also the hypothesis
that autologous blood injections have a direct inﬂuence on the 1 6;5  1(1):90–95
cascade of inﬂammation and cause an early start to recovery
of the degenerated tissue.10
Local inﬁltration of corticosteroids, which is considered
by many  surgeons to be the best option for treating lat-
eral epicondylitis of the elbow, has been questioned. Some
authors have suggested that the improvement observed in
these patients only has partial and temporary efﬁcacy.16
Although some authors12 have reported that application
of PRP is the most promising method for treating lateral
epicondylitis of the elbow, the present study produced dis-
couraging results from prospective analysis on two  different
validated assessment scales, in relation to the increasingly
fashionable use of PRP. There was no statistically signiﬁcant
difference between the forms of treatment over the 180 days
of follow-up of the patients (Tables 5 and 6). Moreover, the
improvement in symptoms seen over the course of the study
period was shown to be statistically the same for the three
substances (Table 7).
However, it is important to emphasize that when more
than two peritendinous inﬁltrations are applied, some unde-
sirable side effects such as local necrosis, tissue atrophy and
tendon tearing may occur.1,8,13 These may be the real reason
why medical professionals prefer to apply PRP, rather than
corticosteroids.
Conclusion
This study did not supply any statistical evidence that PRP
might provide better results than treatment with corticoste-
roids or local anesthetic, in treating lateral epicondylitis of the
elbow.
On the other hand, there was statistical agreement
between the DASH and PRTEE scales. The Portuguese-
language versions of both questionnaires were shown to be
effective for evaluating the evolution of the disease.
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